集團產品精選影片
Essential version- UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity
If variant-specific vaccines and short-interval booster jabs are not a feasible approach to fighting Omicrons and new variants, then “universal (pan) coronavirus vaccines” with innovative new components should be explored and developed to provide sufficient magnitude of broad immunity, durability and breadth of target recognition (spike and non-Spike proteins).
As adaptive memory T-cell immunity plays a central role in protection against infection and control of infectious diseases, T cell responses should be recognized as a measure for long-term vaccine success, an ongoing petition by scientists to regulatory agency.
With the observed pronounced B- and T-cell immunity from this Phase-2 extension trial of 1478 subjects and the incorporation of conserved promiscuous Th and CTL epitope peptides from the Sarbecovirus N, M and S2 proteins, UB-612 offers a potential as a universal vaccine against Omicrons and future VoCs, currently being tested in a US-FDA approved Phase-3 trial to prove the concept.